Lyell Immunopharma (NASDAQ:LYEL) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report released on Thursday morning,Benzinga reports. They currently have a $1.00 target price on the stock.

Lyell Immunopharma Stock Down 9.7 %

Shares of NASDAQ LYEL opened at $0.61 on Thursday. The firm’s fifty day moving average is $0.63 and its 200 day moving average is $0.92. Lyell Immunopharma has a 52 week low of $0.51 and a 52 week high of $3.15. The company has a market cap of $177.14 million, a price-to-earnings ratio of -0.77 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Equities research analysts anticipate that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC grew its holdings in shares of Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after acquiring an additional 182,315 shares during the period. SG Americas Securities LLC boosted its position in shares of Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after purchasing an additional 59,182 shares in the last quarter. Jane Street Group LLC grew its position in shares of Lyell Immunopharma by 63.7% in the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock worth $397,000 after buying an additional 111,917 shares during the period. State Street Corp grew its holdings in Lyell Immunopharma by 1.9% in the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma in the 3rd quarter worth approximately $52,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.